BERKELEY, Calif. and VANCOUVER, British Columbia, Dec. 05, 2017 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp.
("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology
company with a proprietary targeted immunotherapy technology, announced today that Dr. Bill Williams, BriaCell’s President & CEO,
will appear as a guest on the radio show "CEO MONEY."
CEO MONEY, Americas Business Show, Presented By Michael Yorba, airs on www.1190talkradio.iheart.com at 2:00 PM CST (3:00 PM ET, 12:00 PM PST).
To listen to the live interview of "CEO MONEY," please visit www.wfn1.com/listen-live.
The archive of the interview will be posted at www.briacell.com/category/recent-events.
About WFN1
WFN1 discovers new and interesting companies and industries with great stories that are interesting and
potentially rewarding to the investors. The interviews with business leaders are designed to improve the public awareness of
the innovative companies and their productive ideas.
For more info. on WFN1, please visit www.wfn1.com.
About BriaCell
BriaCell is an immuno-oncology focused biotechnology company developing a targeted and safe approach to the
management of cancer. BriaCell's mission is to serve late-stage cancer patients with no available treatment options.
Immunotherapy has come to the forefront of the fight against cancer, harnessing the body's own immune system in
recognizing and selectively destroying cancer cells while sparing normal ones. Immunotherapy, in addition to generally being more
targeted and less toxic than commonly used types of chemotherapy, is also thought to be a potent approach with the potential to
prevent cancer recurrence.
SV-BR-1-GM, the Company's lead product candidate, is derived from a breast cancer cell line genetically
engineered to release granulocyte-macrophage colony-stimulating factor (GM-CSF), a substance that activates the immune system by
allowing the body to recognize and eliminate cancerous cells by inducing tumor-directed T cell and potentially antibody
responses.
The results of two previous Phase I clinical trials (one with the precursor cell line not genetically engineered
to produce GM-CSF and one with SV-BR-1-GM) have been encouraging in patients with advanced breast cancer. Most notably, one patient
with metastatic breast cancer responded to SV-BR-1-GM with substantial reduction in tumor burden including breast, lung, soft
tissue and brain metastases. The company is currently conducting a Phase I/IIa clinical trial for SV-BR-1-GM in patients with
advanced breast cancer. This trial is listed in ClinicalTrials.gov as NCT03066947. The trial is being conducted along
with the co-development of BriaDx™, the Company’s companion diagnostic test. The interim data for the first 10 patients is expected
by the first quarter of 2018. Additionally, the FDA recently approved the roll-over combination study of SV-BR-1-GM with
pembrolizumab [Keytruda; manufactured by Merck & Co., Inc.] or ipilimumab [Yervoy; manufactured by Bristol-Myers Squibb Company]
for patients previously treated with SV-BR-1-GM in the Company’s ongoing Phase I/IIa clinical trial in advanced breast cancer. The
roll-over trial is listed in ClinicalTrials.gov as NCT03328026.
BriaCell is also developing novel, selective protein kinase C delta (PKCδ) inhibitors. PKCδ inhibitors have
shown activity in a number of pre-clinical models of RAS genes’ transformed cancers including breast, pancreatic, non-small cell
lung cancer and neuroendocrine tumors (such as carcinoid tumors).
For additional information on BriaCell, please visit our website: www.briacell.com
Cautionary Note Regarding Forward-Looking Information
Except for the statements of historical fact, this news release contains "forward-looking information" within
the meaning of the applicable Canadian securities legislation which involves known and unknown risks relevant to the Company in
particular and to the biotechnology and pharmaceutical industries in general, uncertainties and other factors that may cause actual
events to differ materially from current expectation. These risks are more fully described in the Company's public filings
available at www.sedar.com.
Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of
the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update
or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact Information
For further information, please contact:
BriaCell Therapeutics Corp.:
Farrah Dean
Manager, Corporate Development
Email: farrah@BriaCell.com
Phone: 1-888-485-6340
